Binhui Biopharmaceutical Co. Ltd.’s BS-001, a recombinant human oncolytic herpes simplex virus type-2 expressing GM-CSF for the potential treatment of solid tumors, has gained an IND approval from the FDA.

LONDON – A significant body of research indicates inhibition of the mitochondrial permeability transition pore (PTP) would reduce neuroinflammation and protect neurons, but the difficulty of finding inhibitors that cross the blood-brain barrier to regulate the pore has left the therapeutic potential largely untapped.

Binhui Biopharmaceutical Co. Ltd.’s BS-001, a recombinant human oncolytic herpes simplex virus type-2 expressing GM-CSF for the potential treatment of solid tumors, has gained an IND approval from the FDA. The development marks the first oncolytic viral candidate developed by a Chinese company to win a go-ahead for trials abroad, it said.

TORONTO – Fluid Biotech Inc. has raised $4.7 million in oversubscribed seed funding to further develop and commercialize the world's first hybrid polymer-metal flow-diverting brain stent for curing brain aneurysms that can lead to stroke. Following successful preclinical studies of the stent, attention now turns to applying this fresh capital to hiring contract manufacturers to prepare for first-in-human implantation and production of the mostly polymer-constructed stent.

PERTH, Australia – Bioinformatic and cell technology company Genieus Genomics Ltd. is using the power of the human genome to build a platform for neurodegenerative diseases to develop diagnostic tests for personalized medicines.

Finding a functional cure to HIV is one of the biggest challenges in modern medicine, a task made so much tougher because of the virus’s ability to incorporate itself permanently into a host’s genome. But Diaccurate SAB, of Paris, thinks it may have a solution – and it’s all down to a discovery showing that the virus seems to make crucial immune CD4 cells go “bumpy”, lose their function and die.

LONDON – Newco Macomics Ltd. has closed its first financing round at £7.4 million (US$10.3 million), enabling it to lay the ground for a new approach to addressing immunosuppression in the tumor microenvironment by modulating disease-specific macrophages.

LONDON – Mestag Therapeutics Ltd. has closed a hefty $45 million seed round to advance development of antibodies targeting activated fibroblasts, in the treatment of cancer and immune diseases.

With a special interest in neurological disorders, Hopstem Biotechnology Co. Ltd. closed a series A++ round to raise nearly ¥100 million (US$15.5 million) to advance hNPC-01, an off-the-shelf induced pluripotent stem cells (iPSC)-derived human forebrain neural progenitor cell product to treat chronic conditions caused by stroke and traumatic brain injuries.

LONDON – Hemab ApS has closed a $55 million series A to take forward treatments for bleeding and thrombosis disorders based on antibodies in-licensed from Novo Nordisk A/S, where the newco’s founder, Johan Henrik Faber, previously led hemophilia drug research.